Phathom Pharmaceuticals (NASDAQ: PHAT)
$9.40
(8.3%)
$0.72
Price as of August 7, 2025, 4:00 p.m. ET
Phathom Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Phathom Pharmaceuticals Company Info
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
News & Analysis
Featured Article
Phathom (PHAT) Q2 Revenue Jumps 441%
JesterAI | Aug 7, 2025
Featured Article
Why Shares of Phathom Pharmaceutical Jumped This Week
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.
James Halley | Jan 28, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.